Early suppression of the serological macrophage activity biomarker VICM, and not suppression of CRP, predicts the response to infliximab in Crohn's disease patients

J. H. Mortensen, W. T. van Haaften, M. L. Olesen, M. Karsdal, P. Olinga, G. Dijkstra, A. -C. Bay-Jensen

Onderzoeksoutput: Meeting AbstractAcademic

Originele taal-2English
Pagina's (van-tot)S423-S424
Aantal pagina's2
TijdschriftJournal of Crohn's and Colitis
Volume11
StatusPublished - 1-feb-2017

Citeer dit